Guangdong Taienkang Pharmaceutical Co., Ltd. (SHE:301263)
China · Delayed Price · Currency is CNY 18.01
-0.18 (-0.99%)
Oct 27, 2026, 4:00 PM EDT
SHE:301263 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Equivalents | 422.43 | 579.72 | 541.96 | 455.64 | 806.79 | 137.63 |
Trading Asset Securities | 150.38 | 40.2 | 122.1 | 251.8 | 240.65 | - |
Cash & Short-Term Investments | 572.81 | 619.93 | 664.06 | 707.45 | 1,047 | 137.63 |
Cash Growth | -7.79% | -6.65% | -6.13% | -32.46% | 661.05% | 47.19% |
Accounts Receivable | 344.17 | 364.56 | 337.06 | 353.04 | 378.49 | 315.95 |
Other Receivables | 1.72 | 8.62 | 2.92 | 4.09 | 4.1 | 1.91 |
Receivables | 345.88 | 373.17 | 339.98 | 357.14 | 382.59 | 317.86 |
Inventory | 116.14 | 98.81 | 105.07 | 86.55 | 80.52 | 76.57 |
Other Current Assets | 44.86 | 40.63 | 33.08 | 36.16 | 22.53 | 11.01 |
Total Current Assets | 1,080 | 1,133 | 1,142 | 1,187 | 1,533 | 543.07 |
Property, Plant & Equipment | 614.1 | 500.76 | 521.27 | 483.74 | 314.54 | 260.24 |
Long-Term Investments | 52.45 | 32.45 | 32.45 | 32.45 | 32.45 | - |
Goodwill | 216.66 | 216.66 | 216.66 | 200.64 | 27.33 | 27.33 |
Other Intangible Assets | 389.43 | 189.51 | 159.25 | 158.19 | 66.01 | 44.46 |
Long-Term Deferred Tax Assets | 117.38 | 93.78 | 57.09 | 32.64 | 34.19 | 29.31 |
Long-Term Deferred Charges | 75.06 | 243.56 | 174.87 | 119.98 | 26.25 | 26.5 |
Other Long-Term Assets | 59.77 | 8 | 7.28 | 14.18 | 5.74 | 10.62 |
Total Assets | 2,605 | 2,417 | 2,311 | 2,229 | 2,040 | 941.52 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Accounts Payable | 254.09 | 172.51 | 168.37 | 121.19 | 56.59 | 46.92 |
Accrued Expenses | 11.47 | 18.75 | 19.53 | 18.7 | 27.64 | 19.68 |
Short-Term Debt | 325.6 | 249.91 | 132.14 | 53.84 | 20.02 | 107.57 |
Current Portion of Long-Term Debt | 65.21 | 28.79 | 24.09 | 12.08 | - | - |
Current Portion of Leases | - | 1.42 | 1.58 | 1.23 | 1.17 | 0.96 |
Current Income Taxes Payable | 23.95 | 9.32 | 21.78 | 37.02 | 41.54 | 16.55 |
Current Unearned Revenue | 13.65 | 12.95 | 3.21 | 4.19 | 5.18 | 9.04 |
Other Current Liabilities | 44.12 | 7.77 | 4.26 | 4.89 | 4.17 | 3.76 |
Total Current Liabilities | 738.09 | 501.41 | 374.95 | 253.13 | 156.33 | 204.48 |
Long-Term Debt | 210.23 | 78.79 | 84 | 108 | - | - |
Long-Term Leases | 2.02 | 2.68 | 0.85 | 1.12 | 1.96 | 0.37 |
Long-Term Unearned Revenue | 15.9 | 13.08 | 15.65 | 16.19 | 19.66 | 19.08 |
Long-Term Deferred Tax Liabilities | 17.07 | 18.75 | 19.21 | 21.28 | 7.68 | 7.79 |
Other Long-Term Liabilities | 64.82 | 61.36 | - | - | - | - |
Total Liabilities | 1,048 | 676.07 | 494.67 | 399.72 | 185.63 | 231.71 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Common Stock | 510.6 | 425.5 | 425.5 | 425.5 | 236.39 | 177.29 |
Additional Paid-In Capital | 769.38 | 857.24 | 896.7 | 900.77 | 1,109 | 116.16 |
Retained Earnings | 438.21 | 428.01 | 484.08 | 502.91 | 508.18 | 416.3 |
Treasury Stock | -223.61 | -39 | -39 | -39 | - | - |
Comprehensive Income & Other | -0.15 | -0.5 | -0.22 | -0.19 | 0.41 | 0.21 |
Total Common Equity | 1,494 | 1,671 | 1,767 | 1,790 | 1,854 | 709.96 |
Minority Interest | 61.97 | 69.95 | 49.33 | 39.41 | -0.16 | -0.15 |
Shareholders' Equity | 1,556 | 1,741 | 1,816 | 1,829 | 1,854 | 709.81 |
Total Liabilities & Equity | 2,605 | 2,417 | 2,311 | 2,229 | 2,040 | 941.52 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Total Debt | 603.06 | 361.59 | 242.65 | 176.27 | 23.16 | 108.9 |
Net Cash (Debt) | -30.25 | 258.34 | 421.41 | 531.18 | 1,024 | 28.73 |
Net Cash Growth | - | -38.70% | -20.67% | -48.14% | 3465.41% | - |
Net Cash Per Share | -0.06 | 0.53 | 0.84 | 1.05 | 2.15 | 0.08 |
Filing Date Shares Outstanding | 554.97 | 508.21 | 508.21 | 508.21 | 510.6 | 510.6 |
Total Common Shares Outstanding | 554.97 | 508.21 | 508.21 | 508.21 | 510.6 | 382.94 |
Working Capital | 341.6 | 631.14 | 767.24 | 934.16 | 1,377 | 338.59 |
Book Value Per Share | 2.69 | 3.29 | 3.48 | 3.52 | 3.63 | 1.85 |
Tangible Book Value | 888.34 | 1,265 | 1,391 | 1,431 | 1,761 | 638.18 |
Tangible Book Value Per Share | 1.60 | 2.49 | 2.74 | 2.82 | 3.45 | 1.67 |
Buildings | - | 441.97 | 448.01 | 208.1 | 205.74 | 207.64 |
Machinery | - | 299.02 | 284.45 | 203.9 | 187.35 | 171.81 |
Construction In Progress | - | 17.37 | 2.44 | 247.02 | 66.37 | 2.01 |